Thromb Haemost 1982; 47(02): 173-176
DOI: 10.1055/s-0038-1657156
Original Article
Schattauer GmbH Stuttgart

A Thiazole Compound with Potential Antithrombotic Activity

E E Nishizawa
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
,
A R Mendoza
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
,
T Honohan
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
,
K A Annis
The Diabetes and Atherosclerosis Research Unit, The Upjohn Company, Kalamazoo, MI, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 20 October 1981

Accepted 03 March 1982

Publication Date:
13 July 2018 (online)

Zoom Image

Summary

A thiazole derivative, 4,5-bis(p-methoxyphenyl)-2-(trifluoromethyl)-thiazole was found to be a potent inhibitor of collagen-induced platelet aggregation, in vitro, using platelets from at least six species, including man. It was active in human platelet-rich plasma at a concentration of 1 ng/ml. While its antiplatelet activity was greater than that of flurbiprofen, its cyclooxygenase activity was equivalent to that of flurbiprofen. Also, compared to flurbiprofen, the thiazole had less anti-inflammatory activity in the hind-paw edema test. The thiazole derivative inhibited platelet aggregation following oral administration in five laboratory species. In the guinea pig it was active at 0.5 mg/kg. The LD50 in mice was greater than 1000 mg/kg (i.p.). This compound, which was designed through a systematic drug development program, may have high potential as an antithrombotic agent.